Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Innovent Biologics's earnings per share without non-recurring items for the
six
months ended in Dec. 2025 was €-0.00.
Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was €0.05.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.
The historical rank and industry rank for Innovent Biologics's EPS without NRI or its related term are showing as below:
During the past 10 years, Innovent Biologics's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 61.00% per year. The lowest was -45.90% per year. And the median was 3.05% per year.
STU:6IB's 3-Year EPS without NRI Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 16.6 * Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
Innovent Biologics's EPS (Basic) for the
six
months ended in Dec. 2025 was €-0.00.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 was €0.06.
Innovent Biologics (STU:6IB) EPS without NRI Explanation
EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Innovent Biologics EPS without NRI Related Terms
Innovent Biologics EPS without NRI Historical Data
* Premium members only.
The historical data trend for Innovent Biologics's EPS without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:6IB vs VRTX, REGN, ALNY: EPS without NRI Comparison
For the Biotechnology subindustry, Innovent Biologics's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Innovent Biologics PE Ratio without NRI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Innovent Biologics's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where Innovent Biologics's PE Ratio without NRI falls into.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.
EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.05
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Innovent Biologics (STU:6IB) has a EPS without NRI of €0.05 as of Dec. 2025. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Innovent Biologics and its competitors. According to the industry distribution chart, Innovent Biologics ranks #999999 out of 1167 companies in the Biotechnology industry.
Is Innovent Biologics' EPS without NRI too high?
Innovent Biologics' current EPS without NRI is €0.05. Based on the distribution chart, Innovent Biologics ranks #999999 out of 1167 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Innovent Biologics has a GF Score™ of 80/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Innovent Biologics' EPS without NRI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Innovent Biologics ranks #999999 out of 1167 companies for EPS without NRI. This places Innovent Biologics in the lower half of its industry. The industry median EPS without NRI is 16.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Biotechnology company?
The median EPS without NRI among Biotechnology companies is 16.60, based on 1,167 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Innovent Biologics and its competitors. For the Biotechnology industry, the median EPS without NRI is 16.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Innovent Biologics's current EPS without NRI is €0.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Innovent Biologics stock overvalued right now?
Based on GuruFocus' analysis, Innovent Biologics (STU:6IB) is currently considered Modestly Undervalued. The stock's GF Value™ is €11.20, compared to a current price of €10.10 — trading 9.8% below its estimated fair value. The current EPS without NRI is €0.05. Innovent Biologics' overall GF Score™ is 80/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Innovent Biologics (STU:6IB), the current EPS without NRI is €0.05 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Innovent Biologics (STU:6IB) Overvalued in 2026?
Based on GuruFocus' analysis, Innovent Biologics stock appears to be undervalued.
The current stock price of €10.10 is trading 9.8% below its estimated GF Value™ of €11.20.
GuruFocus considers Innovent Biologics to be Modestly Undervalued.
Key valuation signals for STU:6IB:
EPS without NRI: €0.05
GF Value™: €11.20 vs. price of €10.10 (9.8% below fair value)
No single metric tells the full story. See the STU:6IB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Innovent Biologics is one of the leading biotechnology companies in China. Listed on the Hong Kong stock exchange in 2018, Innovent has 12 commercialized oncology products and four commercialized nononcology products as of January 2026, and 34 drugs in its research and development pipeline. Its core assets are Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists (NRDL) for the first-line treatment of five major cancers, and mazdutide, a GLP-1/glucagon dual agonist drug for weight loss, fat breakdown, and Type 2 diabetes. Mazdutide is the first domestic GLP-1 drug produced and competes with Eli Lilly and Novo Nordisk in China. Tyvyt's main competition includes drugs from Junshi, Jiangsu Hengrui, BeOne, Merck, and Bristol Myers.
80GF Score
Get the complete analysis for STU:6IB
EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:6IB has been successfully added to your 
